Grantham Mayo Van Otterloo & Co. LLC Acquires 68,006 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Grantham Mayo Van Otterloo & Co. LLC raised its stake in Gilead by 283.7%, buying 68,006 shares to hold 91,973 shares valued at about $10.21 million after the transaction.
• Several Wall Street firms (including Truist, Deutsche Bank, Oppenheimer, Wolfe and Scotiabank) lifted price targets and ratings, leaving Gilead with 23 Buy vs. 4 Hold analyst ratings and a consensus target of $156.72 (rated Moderate Buy).
• Gilead slightly beat quarterly estimates with $1.86 EPS and $7.93B revenue, issued FY2026 guidance of $8.45–$8.85 EPS, and raised its quarterly dividend to $0.82 (annualized $3.28, yield ~2.2%).

Grantham Mayo Van Otterloo & Co. LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 283.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 91,973 shares of the biopharmaceutical company's stock after purchasing an additional 68,006 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC's holdings in Gilead Sciences were worth $10,209,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Csenge Advisory Group grew its holdings in Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock worth $2,375,000 after acquiring an additional 16,288 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Gilead Sciences by 52.1% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock worth $8,713,000 after acquiring an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. lifted its position in shares of Gilead Sciences by 249.1% during the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock worth $1,115,000 after purchasing an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd increased its holdings in shares of Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company's stock valued at $157,139,000 after purchasing an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC bought a new position in Gilead Sciences in the 3rd quarter worth approximately $1,274,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. Truist Financial lifted their target price on Gilead Sciences from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. Oppenheimer boosted their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 11th. Wolfe Research lifted their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, February 12th. Finally, Scotiabank raised their price target on Gilead Sciences from $140.00 to $177.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $156.72.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares of the company's stock, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider owned 120,288 shares of the company's stock, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 309,280 shares of company stock worth $43,935,470 in the last 90 days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $146.63 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $182.03 billion, a PE ratio of 21.66, a PEG ratio of 1.89 and a beta of 0.36. The stock's fifty day simple moving average is $138.73 and its 200 day simple moving average is $126.06.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the firm posted $1.90 earnings per share. Gilead Sciences's revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio (DPR) is currently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.